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Summary We demonstrate the expression of angiotensin 11 type 1 (AT1) receptors in normal and diseased human breast tissues. Using
monoclonal antibody 6313/G2, directed against a specific sequence in the extracellular domain of the AT1 receptor, immunocytochemical
analysis revealed positive immunoreactivity in membrane and cytoplasm of specific cell types. Immunoblotting of solubilized proteins
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) from benign and malignant tumours identified a
single immunoreactive species with a molecular mass of approximately 60 kDa, consistent with that of the mature glycosylated receptor. In
studies of [1251]angiotensin 11 binding using breast membrane preparations, concentrations of specific angiotensin 11 binding sites were found
to range from 1.8 to 100 fmol mg-' protein, with a Kd of approximately 60 nm. Most of the specifically bound [1251]angiotensin II was displaced
by losartan, a specific angiotensin 11 type 1 receptor antagonist, while less was displaced by the AT2 receptor type antagonist, CGP42112A,
thus confirming the prevalence of AT1 receptors in this tissue type. These data suggest that the renin-angiotensin system may be involved in
normal and abnormal breast tissue function.
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Angiotensin II plays a central role in mammalian electrolyte
homeostasis and blood pressure control (Peach, 1977; Vinson etal,
1992). Two main subtypes of angiotensin II receptors, designated
types 1 and 2 (ATl and AT2), have been recognized, but the
majority ofthe well-known actions ofangiotensin II occur via the
ATI subtype (Herblin et al, 1991; Ouali et al, 1992). Local tissue
renin-angiotensin systems have been demonstrated in several
tissues, and in some cases it has been suggested that local produc-
tion of angiotensin II may be particularly concerned in trophic
actions (Vinson et al, 1995a).
The availability ofour recently developed monoclonal antibody
(6313/G2) to the ATI receptor subtype (Barker et al, 1993a) has
facilitated the further study of its distribution (Vinson et al,
1995a). We describe here studies investigating the presence ofthe
ATl receptor in normal and diseased breast.
MATERIAL AND METHODS
Fresh breast tissue samples were obtained with appropriate
informed consent from 22 patients undergoing breast surgery.
Samples obtained for the study were selected by the pathologist
responsible for handling the specimen, divided and the larger
portion immediately snap frozen in liquid nitrogen for future
immunocytochemical and biochemical assay. The remainder
was fixed in 10% formalin-saline for 24 h before paraffin wax
embedding.
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Staining procedure
Breast tissue sections (4 im) were dewaxed in xylene and de-
hydrated in alcohol at room temperature. Human adrenal gland
sections were used as positive controls.
Sections were then immersed in endogenous peroxidase
blocking solution (3 ml of 100 volume hydrogen peroxide and
97 ml of methanol; 15 min), washed in tap water (10 min) and
distilled water (5 min). Sections were immersed in 10 mm citrate
buffer, pH 6.0, covered loosely with 'Saranwrap' (Dow Chemical
Co.) and boiled in a microwave oven for 10 min at 630 w (H2500
BioRad, Watford, Herts., UK). After standing for 10 min in hot
buffer, sections were washed in tap water (5 min) and transferred
to 0.05 M Tris-buffered saline, pH 7.6 (TBS).
Tissue sections were then incubated with normal rabbit serum
(Dako, High Wycombe, Bucks., UK) diluted 1:5 in Tris-buffered
saline (20 min) and incubated (60 min) with mouse primary anti-
body 6313/G2 (Barker et al, 1993a) in RPMI-1640 culture medium
(ICN-Flow Ltd., High Wycombe, Bucks., UK), then washed twice
and left to soak in TBS (5 min). Sections were then exposed to
biotinylated rabbit anti-mouse IgG complex (Dako), diluted 1:400
in TBS (30 min), washed in TBS then incubated for 30 min with
avidin- biotin complex (Dako) and washed again in TBS.
Visualization of receptor was achieved through the diaminobenzi-
dine hydrochloride (DAB)-hydrogen peroxide chromogen
substrate reaction (Sigma Chemical Co., Poole, Dorset, UK) using
10 ml of 0.05 M TBS, 6 mg of DAB and 0.1 ml of fresh 3%
hydrogen peroxide for 10 min. Slides were washed in water (10
min), counterstained in Gill's haematoxylin (2 min), rewashed in
water (5 min), differentiated briefly in acid alcohol (10 ml of 1%
hydrochloric acid in 990 ml of 70% industrial methylated spirit
(IMS; BDH Laboratory Supplies, Poole, Dorset, UK), dehydrated
in IMS, cleared with xylene twice and mounted in Canada balsam
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Figure 1 Immunostaining of breast tissue for angiotensin 11 type 1 receptor
(AT1), using monoclonal antibody 6313/G2. Peroxidase staining (brown)
indicates receptor protein, nuclei are counterstained with haematoxylin.
Normal (A) and malignant (B) tissue is illustrated. Bar = 50 ,um
(BDH). Negative control sections were treated similarly except that
culture medium containing non-specific mouse IgG was substituted
for primary antibody. The sections were viewed under a Leitz
Laborlux microscope.
Membrane preparation
Tissues were retrieved from liquid nitrogen, and samples of
approximately g wet weight were homogenized in a homogen-
izer (Polytron, Kinematica AG, Switzerland) in ice-cold 50 mm
Tris-HCl buffer, pH 7.4, containing 1 gg ml-1 each of protease
inhibitors aprotinin and soybean trypsin inhibitor and 30 jig ml-1
phenylmethylsulphonyl fluoride (Sigma) at 4'C. Homogenates
were centrifuged at 800 g for 10 min at 4°C. The supernatant was
recentrifuged at 100 000 g for 1 h and the resultant pellet resus-
pended in Tris-HCl containing protease inhibitors, 100 mm
sodium chloride, 6 mm magnesium chloride (THP) and % bovine
serum albumin (BSA) and used immediately or stored at -70°C
until used.
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Figure 2 Scatchard plots for radiolabelled angiotensin 11 binding to
(A) normal and (B) malignant breast tissue membrane preparations. The
specific binding of radiolabelled ligand is expressed per mg of protein. NB:
different scales for (A) and (B)
Immunoblotting
Solubilized membrane fractions, equivalent to 300 jg of protein,
as estimated by the method ofLowry et al (1951), were loaded into
each well and subjected to sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE), using the method of
Laemmli (1970) with prestained SDS-PAGE molecular weight
standards (BioRad, Richmond, CA, USA) in an adjacent well. The
gel (7.5%) was run at 200 V for 3 h. Proteins were then electro-
transferred to Hybond-ECL nitrocellulose membrane (Amersham
International, High Wycombe, Bucks., UK) overnight at 60 mA,
using the following transfer buffer: 9 g of Trizma base, 43.2 g of
glycine and 600 ml of methanol made up to 3 1 in distilled water.
The molecular marker lane was cut off and stained with
Coumassie blue (Sigma). Non-specific binding sites on the gel
were then blocked with 10% milk powder (Marvel; Premier
British Journal ofCancer (1997) 75(9), 1279-1283
0
0
0
x
a)
C 70 m
2.27
2.0
1.8 -
1.6
B
4 I
2 6 8
0.3 i I I I I
1 .'
C
%'-W-I CancerResearch Campaign 1997Angiotensin I/ type 1 receptor expression 1281
Total binding All Losartan CGP42112A
Figure 3 Inhibition of radiolabelled angiotensin ll binding by unlabelled
angiotensin ll, losartan (DuP753) or CGP42112A
Brands UK Ltd, Stafford, Staffs., UK) for 1 h. Membranes were
washed twice (10 min and 5 min) with 1% phosphate-buffered
saline (PBS)-T (500 gl ofTween made up to 500 ml volume with
PBS) and incubated with primary antibody (6313/G2 in RPMI-
1640 culture medium) diluted 1:20 in PBS-T for 1 h. Membranes
were then washed twice in PBS-T, incubated for 1 h with horse-
radish peroxidase-linked sheep anti-mouse IgG (Amersham)
diluted 1:5000 in PBS-T. Positive bands were visualized using
ECL Westem blotting detection reagent (Amersham). All incuba-
tions were at room temperature.
Radioligand binding
Membrane suspensions (300 gg of protein per tube) were.
incubated for 1 h at room temperature with 0.1 nM [1251]AII
(Amersham, 2000 Ci mmol-1) in the presence of unlabelled
angiotensin II at concentrations from 0.39 nm to 50 nm in a final
incubation volume of 150 gl of THP. To determine receptor
subtypes, incubations were also carried out in the presence of
1 gM DUP 753 (Losartan, Du Pont Co., DE, USA) or 0.1 ,UM
CGP42112A (Ciba-Geigy, Basle, Switzerland). After 60 min at
room temperature, reactions were terminated by the addition of
800 ,ul ofcold Tris-HCl. Each tube was centrifuged at 10 000 g for
5 min and the pellet washed and recentrifuged. Radioactivity
bound to pellets was estimated using a gamma-counter (LKB-
Wallac OY, Finland) and the results analysed by the method of
Scatchard (1949).
RESULTS
Immunocytochemistry
Histological material obtained from 22 patients was examined.
Results obtained with normal and malignant breast tissues are
shown in Figure 1. In normal tissue and in benign disease, ATI
receptor is distributed in the cytoplasm of epithelial cells. In the
malignant cases examined, there was graded distribution of
staining intensity, which varied from cell to cell, and from one part
of a tumour to another. This was true for all histological types of
malignant tumours. Thus, although virtually all epithelial cells
Figure 4 Immunoblotting of solubilized membrane preparations from
malignant (lane 1) and benign (lane 2) breast tissue, using monoclonal
antibody 6313/G2
were positively stained in normal and benign tissues, malignant
tissues contained both positive- and negative-reacting cells. No
nuclear staining was observed in either the benign or malignant
groups. All staining reaction was abolished by substituting the
primary antibody with non-specific mouse IgG.
Binding studies
Analysis of ligand binding data confirms the presence of the ATI
receptor (Figures 2 and 3). Two samples of tissue with benign
breast disease and eight from malignant breast tumours gave values
for concentrations of receptors ranging from 1.8 to 100 fmol mg-'
protein, and dissociation constants (kd) of approximately 60 nm.
The ATI antagonist, losartan, displaced most of the specifically
bound ['251]AII, while the AT2 antagonist CGP42112A was less
effective (Figure 3).
Immunoblotting
Using solubilized membranes from human benign and malignant
breast tumours, immunoblotting studies after SDS-PAGE fraction-
ation revealed a single immunoreactive band with a molecular
mass ofapproximately 60 kDa (Figure 4).
DISCUSSION
The development of an antibody to the angiotensin II type
receptor has enabled us to extend our knowledge of the receptor's
distribution. The antibody is highly specific: it identifies the
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receptor in COS-7 cells that have been transfected with the gene
coding for the receptor, but not in untransfected cells (Barker et al,
1993a,b), and it also identifies the receptor accurately in a variety
of tissues, including the adrenal cortex, the vasculature and in
epithelial tissues that have been shown to be angiotensin II respon-
sive by other means, including ligand binding and functional
assays (Vinson et al, 1995a,b; Saridogan et al, 1996a,b).
Taken together, the data presented here clearly demonstrate the
presence of angiotensin II type 1 receptors in both normal and
diseased human breast tissue. The data are consistent with our
findings in other tissue types (Vinson et al, 1995a) that the
receptor is present in epithelial (and endothelial) cells and may be
localized on the membrane or in cytoplasmic sites (Figure 1). It is
known from other studies that the receptor may be intemalized
within the cell and recycled to the cell surface, and that its cellular
distribution thus depends on the extent of receptor occupancy
by the hormone (Ullian and Linas, 1989). Scatchard analysis
confirms the presence of receptor-like specific angiotensin II
binding sites, and the use of the subtype-specific antagonists,
losartan and CGP42112A, confirms that most of these sites are
indeed ATI receptors (Figures 2 and 3). The possibility of a
biphasic Scatchard plot for the normal tissue cannot be excluded
(see Figure 2a), but it should be remembered that these reflect
both the ATI and AT2 receptor-binding capacities (cf. Figure 3).
Both the kd of the receptor and its molecular mass, as determined
by immunoblotting (Figure 4), are consistent with findings for
the ATI receptor in othertissues (Barker et al, 1993a,b; Desamaud
et al, 1993).
It is of particular interest that both normal breast tissue and
tumours express the receptor in epithelial cells of both ducts and
lobules, suggesting a role for this hormone in the maintenance of
tissue structure and function. Indeed, recent work now proposes a
role of angiotensin II as a tissue or paracrine hormone (Vinson et
al, 1995a), and our own studies on the distribution of the ATI
receptor confirm this. In brief, several localized tissue renin-
angiotensin systems have been described, particularly in the
adrenal gland, uterus (Capponi and Catt, 1980), heart (Okura et al,
1992), pituitary and brain (Mendelson et al, 1984; Trolliet and
Phillips, 1992). In the present context, it is therefore pertinent that
significant levels of angiotensin-converting enzyme activity have
been measured in human breast tissue (Dzau, 1993). The existence
of local RAS systems in addition to the systemic RAS suggests
that the generation ofangiotensin II in close proximity to its recep-
tors may be important in ensuring that tissue-specific functions are
precisely regulated, without concomitant inappropriate actions in
unrelated tissues.
From comparison with other tissues, it is possible that the
expression of angiotensin receptors in breast tissue may reflect a
role in cell growth and/or development (Vinson et al, 1992, 1995a;
Varela and Saez, 1993). Given the complexity of the local and
systemic RAS mechanisms, it is also conceivable that these func-
tions may be perturbed in disease. For example, it has been shown
that converting enzyme inhibitors and peptide angiotensin II
antagonists are capable of reducing the growth of neuroblastoma
cells in culture (Chen et al, 1993) and also that angiotensin recep-
tors are down-regulated in hepatic tumours, causing selective
arterial vasoconstriction in surrounding normal liver (Sitzman et
al, 1994). A similar observation has been made in breast cancer
patients (Noguchi et al, 1988) and is already being exploited in
regional intra-arterial infusions of chemotherapeutic agents. From
the examples we give here, it is obvious that malfunction oftissue
RAS could give rise to any of a spectrum of quite unrelated prob-
lems. In view of the widespread incidence of the ATI receptor in
epithelial tissue, and the potential for involvement of the tissue
RAS in growth-promoting and tissue-modelling events, one
further striking possibility is that the presence of angiotensin
receptors in malignant breast epithelial cells raises the prospect
that All may be involved in the development ofcancer.
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